“Having broken out of a three-week consolidation, the Nifty is expected to sustain its upward momentum. The index is now targeting levels of 25,200–25,600. On the downside, the earlier resistance at ...

Covid-19 changed the trajectory of a small vaccine venture. Now, its researchers hope to develop new mRNA jabs for even more ...

In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector ...

Singapore is negotiating with the U.S. to ease tariffs on pharmaceuticals and secure access to advanced chips amid shifting ...

CHARLESTON, W.Va. –State Attorney General J.B McCuskey announcing Friday that they have distributed nearly $3.5 million dollars to counties and cities in West Virginia as part of a recently ...

Pfizer reaffirmed $10–$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug ...

Pieter Cullis a co-founder and have shares in Acuitas Therapeutics, the company that provided the LNP enabling the Pfizer/BioNTech COVID-19 vaccine. He receives funding from CIHR. University of ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Pfizer recently said it wouldn't continue development of its weight loss candidate danuglipron, a once-daily pill, after a patient in a clinical trial experienced liver injury -- the problem ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Putin sees opportunity for the ‘first time in decades’ for a relationship recalibration A Day in Life of Sailors Working 24/7 Inside World’s Largest Containerships Pfizer's CEO said the ...

Pfizer PFE shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning. Still, Pfizer stock has fallen 10% year to date ...